Latest Industry Insights
Biosciences in 2022: Bioscience Reaps Benefits From the Cloud
Technological innovations brought in as a result of COVID-19 could produce dramatic changes to how we do science. In this insight, Synthace co-founder Markus Gershater previews a cloud-first future for bioscience.
How Do Spreadsheets Hold Back Pharma Innovation?
Technology Networks spoke to Jesse Harris to learn why spreadsheets can be a bottleneck for pharma research and explore how they compare to laboratory informatics tools.
Sustainability and Research: Finding a Balance
Laboratories often consume three to 10 times more energy than typical non-laboratory areas of universities. We spoke to Dr Susan Simon of the Medical Research Council to learn more about their commitment to sustainability and transformation to net zero by 2040.
Designing in Sustainability in Science
With a reliance on single-use plastics, significant waste and high energy usage, the carbon footprint of the biopharma industry is large. If we are to accelerate the path to net zero, it is therefore critical to ensure sustainability in science.
Uncovering Real-World Patient Insights With Social Media and NLP
Historically, drug researchers have relied on methods such as focus groups and questionnaires for first-person accounts of patient-reported outcomes. Social media has emerged as a lower cost alternative that is increasingly accepted as a reputable source of information by the research community.
Transformative Models for Research and Drug Discovery
Technology Networks spoke to Dr. Mark Kotter, CEO and founder of bit.bio to learn about opti-ox™ and the development, benefits and applications of ioSkeletal Myocytes.
Reinventing Neuroscience Drug Discovery
Technology Networks had the pleasure of speaking with Saul Kato, the CEO of Herophilus, to learn more about how the company plans to reinvent neuro drug discovery, by combining human brain models, scaled biology and machine learning to decode brain disease.
Accelerating Preclinical Biologics Development
Quick to Clinic from Thermo Fisher Scientific aims to accelerate preclinical development, enabling more rapid biologic drug development. To learn more about this solution, we spoke to Paul Jorjorian.
What Is the Best Approach to Psychedelic Therapy? An Interview With Field Trip’s Ronan Levy
We spoke to co-founder and executive chairman, Ronan Levy, to find out more about Field Trip’s approach to psychedelic therapy and why 2021 has been such a significant year in psychedelics.
NanoDrop 20 Years On
In this interview, Patrick Brown tells us more about the evolution of NanoDrop over the past 20 years, highlights some of the most important improvements during this time and explores what the future may hold for the technology.